Regnum Corp.
RGMPOTC
Healthcare
New York City, NY, US1 employees
—
At A Glance
1
Regnum Corp.
2
No significant events in the past 90 days.
—
Market Cap
—
Revenue
—
Net Income
Employees1
Fundamentals
How The Business Makes Money
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIK0001716324
ISINUS75915R1068
CUSIP75915R106
Phone877 313 2232
Address600 Third Avenue, New York City, NY, 10016, US
SEC EDGAR